A Prospective Registry to Enable Collection of Standardized Routine Care Oncology Patient Data

October 16, 2025 updated by: N-Power Medicine

A Prospective Registry for Collecting Standardized, Routine Care Data to Characterize Patients, Treatment Patterns, Safety and Treatment Effectiveness in Adult Oncology Patients

This is an observational registry for patients at participating oncology centers. The data collection includes but is not limited to baseline variables, treatments given and outcome data. Patient surveys are also included. The aim of the study is to generate rich and standardized data for patients and to help enable more patients participate in clinical trials and contribute to research and development.

Study Overview

Status

Recruiting

Conditions

Detailed Description

This is an observational registry for patients at participating oncology centers. The data collection includes but is not limited to baseline variables, treatments given and outcome data. Patient surveys are also included. The aim of the study is to generate rich and standardized data for patients and to help enable more patients participate in clinical trials and contribute to research and development.

Study Type

Observational

Enrollment (Estimated)

20000

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

  • United States
    • California
      • Monterey, California, United States, 93940
        • Recruiting
        • Pacific Cancer Care
        • Contact:
        • Contact:
          • Registry Help Line
          • Phone Number: 833-4NPM-REG
    • Delaware
      • Dover, Delaware, United States, 19901
        • Recruiting
        • Bayhealth Cancer Center-Kent
        • Contact:
        • Principal Investigator:
          • Iftekar Khan, MD
      • Milford, Delaware, United States, 19963
        • Recruiting
        • Bayhealth Cancer Center- Sussex
        • Contact:
        • Principal Investigator:
          • Iftekar Kahn, MD
    • Illinois
    • New Mexico
      • Albuquerque, New Mexico, United States, 87109
    • Pennsylvania
      • Paoli, Pennsylvania, United States, 19301
        • Recruiting
        • Lankenau Medical Center
        • Contact:
        • Principal Investigator:
          • Paul Gilman, MD
    • Texas
      • Houston, Texas, United States, 77030
        • Recruiting
        • oncology Consultants, P.A.
        • Contact:
        • Contact:
          • Phone Number: 1-833-4NPM-REG

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Sampling Method

Non-Probability Sample

Study Population

All patients at oncology sites participating in the registry.

Description

Inclusion Criteria:

Be a patient at a site (oncology) participating in the Registry Be at least 18 years old Be able and willing to provide signed informed consent

Exclusion Criteria:

Prisoners/imprisonment at time of screening for eligibility Patients who cannot consent without utilization of a legally authorized representative

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Treatment Effectiveness - Time to treatment discontinuation
Time Frame: This is an open-ended registry where data will be collected, analysed and presented regularly over time.
Effectiveness outcomes of treatments used in routine clinical care (such as for instance time to treatment discontinuation ) will be captured
This is an open-ended registry where data will be collected, analysed and presented regularly over time.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

N-Power Medicine

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

August 1, 2022

Primary Completion (Estimated)

January 1, 2099

Study Completion (Estimated)

January 1, 2099

Study Registration Dates

First Submitted

February 11, 2025

First Submitted That Met QC Criteria

March 10, 2025

First Posted (Actual)

March 14, 2025

Study Record Updates

Last Update Posted (Estimated)

October 20, 2025

Last Update Submitted That Met QC Criteria

October 16, 2025

Last Verified

October 1, 2025

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • NPM-001

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe